Aethlon Medical Cuts Loss in Fiscal Q1
Aethlon Medical (NASDAQ:AEMD), a medical technology developer focused on its lead Hemopurifier device for cancer and viral diseases, reported fiscal first-quarter results for the period ended June 30, 2025. The main news from the release was a narrowed loss per share for the three months ended June 30, 2025, compared to the prior year, reflecting aggressive cost reductions, and continued clinical advancement in its Australian oncology trial, but no revenue as the company remains in pre-commercial development. The company posted a net loss per share of $(0.85) (GAAP), and a substantial improvement from $(2.76) in the same period last year (GAAP)—driven by reduced operating expenses. With streamlined costs and some key clinical milestones reached, the quarter was marked by careful resource management but ongoing funding uncertainty.
Source: Analyst estimates for the quarter provided by FactSet.
Aethlon Medical (NASDAQ:AEMD) is a clinical-stage medical device developer developing the Hemopurifier, a device designed to filter harmful substances such as exosomes and viruses from the bloodstream. The Hemopurifier targets conditions such as cancer, viral infections, and emerging diseases, with current clinical studies focusing on oncology (cancer treatment).
Source Fool.com
